AGC Biologics is partnering with Repair Biotechnologies to develop and manufacture a novel mRNA therapy to rapidly stabilize and reduce the size of atherosclerotic plaques in major blood vessels. Rupture of unstable plaque and subsequent heart attack or stroke is the leading cause of death, accounting for 27% of all human mortality.

“Developing a novel mRNA therapeutic as a part of the vital goal of curing atherosclerotic cardiovascular disease is a complex task, and robust manufacturing is critical to our progress,” said Reason, CEO and co-founder, Repair Biotechnologies. “We chose AGC Biologics because they have mastered the entire production chain for therapeutics of this class, eliminating critical risks and delays to provide a fast and reliable path to the GMP drug product needed for our clinical trials. We are pleased to work with AGC Biologics to advance our mission to help people enjoy longer, healthier lives.”

For Repair Biotechnologies, navigating the complex manufacturing landscape is a critical challenge. By consolidating the entire production journey, AGC Biologics provides a streamlined and de-risked path to the clinic and market without expensive services or complex technologies.

This collaboration will leverage AGC Biologics’ mRNA manufacturing knowledge and expertise that allows innovators to manage the entire process from the initial plasmid DNA blueprint to the final drug product encapsulated in lipid nanoparticles with a single, experienced partner.

“For clients like Repair Biotechnologies, we can be the most cost-effective, reliable, cGMP provider that can take life-saving mRNA treatments through the journey from preclinical to commercial stages,” said Alberto Santagostino, CEO, AGC Biologics. “As the friendly CDMO expert, this is emblematic of our no-frills, expert approach is economical while never compromising good manufacturing and quality. Our approach ensures developers can radically transform quality of life around the world without breaking the bank.”